- Home
- AFCG vs BMEA Comparison
AFCG vs BMEA Comparison
Compare AFCG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- BMEA
- Stock Information
- Founded
- AFCG 2020
- BMEA 2017
- Country
- AFCG United States
- BMEA United States
- Employees
- AFCG N/A
- BMEA N/A
- Industry
- AFCG Real Estate Investment Trusts
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- BMEA Health Care
- Exchange
- AFCG Nasdaq
- BMEA Nasdaq
- Market Cap
- AFCG 210.5M
- BMEA 209.8M
- IPO Year
- AFCG 2021
- BMEA 2021
- Fundamental
- Price
- AFCG $9.30
- BMEA $4.18
- Analyst Decision
- AFCG Buy
- BMEA Buy
- Analyst Count
- AFCG 6
- BMEA 13
- Target Price
- AFCG $12.00
- BMEA $37.25
- AVG Volume (30 Days)
- AFCG 150.7K
- BMEA 827.4K
- Earning Date
- AFCG 11-13-2024
- BMEA 10-29-2024
- Dividend Yield
- AFCG 14.16%
- BMEA N/A
- EPS Growth
- AFCG N/A
- BMEA N/A
- EPS
- AFCG 0.40
- BMEA N/A
- Revenue
- AFCG $43,164,939.00
- BMEA N/A
- Revenue This Year
- AFCG N/A
- BMEA N/A
- Revenue Next Year
- AFCG N/A
- BMEA N/A
- P/E Ratio
- AFCG $23.28
- BMEA N/A
- Revenue Growth
- AFCG N/A
- BMEA N/A
- 52 Week Low
- AFCG $7.45
- BMEA $3.61
- 52 Week High
- AFCG $10.88
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- AFCG 39.64
- BMEA 23.76
- Support Level
- AFCG $9.22
- BMEA $5.55
- Resistance Level
- AFCG $9.67
- BMEA $6.06
- Average True Range (ATR)
- AFCG 0.19
- BMEA 0.49
- MACD
- AFCG -0.02
- BMEA -0.08
- Stochastic Oscillator
- AFCG 8.45
- BMEA 0.50
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team's deep network and significant credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value and cash flows.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.